IE73662B1 - Cyclosporin compositions for oral administration - Google Patents
Cyclosporin compositions for oral administrationInfo
- Publication number
- IE73662B1 IE73662B1 IE922082A IE922082A IE73662B1 IE 73662 B1 IE73662 B1 IE 73662B1 IE 922082 A IE922082 A IE 922082A IE 922082 A IE922082 A IE 922082A IE 73662 B1 IE73662 B1 IE 73662B1
- Authority
- IE
- Ireland
- Prior art keywords
- component
- composition according
- glycerides
- cyclosporin
- tri
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 143
- 229960001265 ciclosporin Drugs 0.000 title claims abstract description 64
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title claims abstract description 60
- 108010036949 Cyclosporine Proteins 0.000 title claims abstract description 59
- 229930182912 cyclosporin Natural products 0.000 title claims abstract description 28
- 229930105110 Cyclosporin A Natural products 0.000 title claims abstract description 26
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 31
- 235000005687 corn oil Nutrition 0.000 claims abstract description 23
- 239000002285 corn oil Substances 0.000 claims abstract description 21
- 239000004094 surface-active agent Substances 0.000 claims abstract description 9
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 73
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 239000012071 phase Substances 0.000 claims description 28
- 239000000047 product Substances 0.000 claims description 27
- 150000003626 triacylglycerols Chemical class 0.000 claims description 21
- 239000004530 micro-emulsion Substances 0.000 claims description 18
- OYHQOLUKZRVURQ-HZJYTTRNSA-N linoleic acid group Chemical group C(CCCCCCC\C=C/C\C=C/CCCCC)(=O)O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 13
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 13
- 235000021313 oleic acid Nutrition 0.000 claims description 12
- 239000001828 Gelatine Substances 0.000 claims description 11
- 229920000159 gelatin Polymers 0.000 claims description 11
- 235000020778 linoleic acid Nutrition 0.000 claims description 11
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 10
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 10
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 10
- 239000005642 Oleic acid Substances 0.000 claims description 10
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 10
- 239000000194 fatty acid Substances 0.000 claims description 10
- 235000019322 gelatine Nutrition 0.000 claims description 10
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 claims description 9
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 9
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 8
- 229930195729 fatty acid Natural products 0.000 claims description 8
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 8
- 150000004665 fatty acids Chemical class 0.000 claims description 7
- 238000005809 transesterification reaction Methods 0.000 claims description 7
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims description 6
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 5
- 239000008158 vegetable oil Substances 0.000 claims description 5
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000004359 castor oil Substances 0.000 claims description 4
- 235000019438 castor oil Nutrition 0.000 claims description 4
- 239000007795 chemical reaction product Substances 0.000 claims description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 4
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 3
- ZMKGDQSIRSGUDJ-VSROPUKISA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-30-propyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,1 Chemical compound CCC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-VSROPUKISA-N 0.000 claims description 2
- ZMKGDQSIRSGUDJ-UHFFFAOYSA-N NVa2 cyclosporine Natural products CCCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-UHFFFAOYSA-N 0.000 claims description 2
- 108010019249 cyclosporin G Proteins 0.000 claims description 2
- 239000008346 aqueous phase Substances 0.000 claims 1
- 125000005481 linolenic acid group Chemical group 0.000 claims 1
- 150000002889 oleic acids Chemical class 0.000 claims 1
- 239000002552 dosage form Substances 0.000 abstract description 9
- 238000009472 formulation Methods 0.000 abstract description 8
- 239000006186 oral dosage form Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 description 15
- 239000008280 blood Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 239000002775 capsule Substances 0.000 description 13
- 229960004063 propylene glycol Drugs 0.000 description 13
- 238000013103 analytical ultracentrifugation Methods 0.000 description 11
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 11
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 238000007127 saponification reaction Methods 0.000 description 7
- 150000004671 saturated fatty acids Chemical class 0.000 description 7
- 235000021355 Stearic acid Nutrition 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 235000021314 Palmitic acid Nutrition 0.000 description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 239000011630 iodine Substances 0.000 description 5
- -1 medium chain fatty acid triglycerides Chemical class 0.000 description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 5
- 239000008117 stearic acid Substances 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000007791 liquid phase Substances 0.000 description 4
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 4
- 239000008389 polyethoxylated castor oil Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000013049 sediment Substances 0.000 description 4
- 108010036941 Cyclosporins Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- ONCCWDRMOZMNSM-FBCQKBJTSA-N compound Z Chemical compound N1=C2C(=O)NC(N)=NC2=NC=C1C(=O)[C@H]1OP(O)(=O)OC[C@H]1O ONCCWDRMOZMNSM-FBCQKBJTSA-N 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 239000001149 (9Z,12Z)-octadeca-9,12-dienoate Substances 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 2
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- FLIACVVOZYBSBS-UHFFFAOYSA-N Methyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC FLIACVVOZYBSBS-UHFFFAOYSA-N 0.000 description 2
- HPEUJPJOZXNMSJ-UHFFFAOYSA-N Methyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC HPEUJPJOZXNMSJ-UHFFFAOYSA-N 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003833 bile salt Substances 0.000 description 2
- 229940093761 bile salts Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 239000007963 capsule composition Substances 0.000 description 2
- LDVVMCZRFWMZSG-UHFFFAOYSA-N captan Chemical compound C1C=CCC2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C21 LDVVMCZRFWMZSG-UHFFFAOYSA-N 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920001993 poloxamer 188 Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- DTOSIQBPPRVQHS-UHFFFAOYSA-N α-Linolenic acid Chemical compound CCC=CCC=CCC=CCCCCCCCC(O)=O DTOSIQBPPRVQHS-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WTTJVINHCBCLGX-UHFFFAOYSA-N (9trans,12cis)-methyl linoleate Natural products CCCCCC=CCC=CCCCCCCCC(=O)OC WTTJVINHCBCLGX-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- OVYMWJFNQQOJBU-UHFFFAOYSA-N 1-octanoyloxypropan-2-yl octanoate Chemical compound CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC OVYMWJFNQQOJBU-UHFFFAOYSA-N 0.000 description 1
- OURWLMNRUGYRSC-UHFFFAOYSA-N 12-(1-hydroxypropan-2-yloxy)octadecanoic acid Chemical compound CCCCCCC(OC(C)CO)CCCCCCCCCCC(O)=O OURWLMNRUGYRSC-UHFFFAOYSA-N 0.000 description 1
- DVWSXZIHSUZZKJ-UHFFFAOYSA-N 18:3n-3 Natural products CCC=CCC=CCC=CCCCCCCCC(=O)OC DVWSXZIHSUZZKJ-UHFFFAOYSA-N 0.000 description 1
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- WITKSCOBOCOGSC-UHFFFAOYSA-N 2-dodecanoyloxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCCCC WITKSCOBOCOGSC-UHFFFAOYSA-N 0.000 description 1
- JZSMZIOJUHECHW-GTJZZHROSA-N 2-hydroxypropyl (z,12r)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCC(C)O JZSMZIOJUHECHW-GTJZZHROSA-N 0.000 description 1
- BJRXGOFKVBOFCO-UHFFFAOYSA-N 2-hydroxypropyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(C)O BJRXGOFKVBOFCO-UHFFFAOYSA-N 0.000 description 1
- LNJCGNRKWOHFFV-UHFFFAOYSA-N 3-(2-hydroxyethylsulfanyl)propanenitrile Chemical compound OCCSCCC#N LNJCGNRKWOHFFV-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 241001550224 Apha Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 206010016948 Food interaction Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- PKIXXJPMNDDDOS-UHFFFAOYSA-N Methyl linoleate Natural products CCCCC=CCCC=CCCCCCCCC(=O)OC PKIXXJPMNDDDOS-UHFFFAOYSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 229920002700 Polyoxyl 60 hydrogenated castor oil Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- WMNULTDOANGXRT-UHFFFAOYSA-N bis(2-ethylhexyl) butanedioate Chemical compound CCCCC(CC)COC(=O)CCC(=O)OCC(CC)CCCC WMNULTDOANGXRT-UHFFFAOYSA-N 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- PWEOPMBMTXREGV-UHFFFAOYSA-N decanoic acid;octanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCC(O)=O.CCCCCCCC(O)=O.CCCCCCCCCC(O)=O.CCCCCCCCCC(O)=O PWEOPMBMTXREGV-UHFFFAOYSA-N 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229960000878 docusate sodium Drugs 0.000 description 1
- LLRANSBEYQZKFY-UHFFFAOYSA-N dodecanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCCCCCC(O)=O LLRANSBEYQZKFY-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- QYDYPVFESGNLHU-UHFFFAOYSA-N elaidic acid methyl ester Natural products CCCCCCCCC=CCCCCCCCC(=O)OC QYDYPVFESGNLHU-UHFFFAOYSA-N 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- CAMHHLOGFDZBBG-UHFFFAOYSA-N epoxidized methyl oleate Natural products CCCCCCCCC1OC1CCCCCCCC(=O)OC CAMHHLOGFDZBBG-UHFFFAOYSA-N 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229940049918 linoleate Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- QGBRLVONZXHAKJ-UHFFFAOYSA-N methyl arachidate Chemical compound CCCCCCCCCCCCCCCCCCCC(=O)OC QGBRLVONZXHAKJ-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- DVWSXZIHSUZZKJ-YSTUJMKBSA-N methyl linolenate Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(=O)OC DVWSXZIHSUZZKJ-YSTUJMKBSA-N 0.000 description 1
- QYDYPVFESGNLHU-KHPPLWFESA-N methyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC QYDYPVFESGNLHU-KHPPLWFESA-N 0.000 description 1
- 229940073769 methyl oleate Drugs 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000002103 osmometry Methods 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 1
- 102220305863 rs1015663503 Human genes 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000001589 sorbitan tristearate Substances 0.000 description 1
- 235000011078 sorbitan tristearate Nutrition 0.000 description 1
- 229960004129 sorbitan tristearate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
- C11C3/00—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom
- C11C3/04—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by esterification of fats or fatty oils
- C11C3/06—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by esterification of fats or fatty oils with glycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nanotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Transplantation (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Medical Informatics (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Fats And Perfumes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Confectionery (AREA)
Abstract
Pharmaceutical compositions comprising a cyclosporin in a novel galenic formulations for oral administration. The compositions typically comprise a cyclosporin, 1,2-propylene glycol, a mixed mono-, di- and tri-glyceride and a hydrophilic surfactant. Further a refined glycerol-transesterified corn oil is provided representing a mixed mono-, di- and tri-glyceride suitable for the novel formulation. Dosage forms include in particular oral dosage forms.
Description
CYCLOSPORIN COMPOSITIONS FOR ORAL ADMINISTRATION The present invention relates to novel galenic formulations, in particular novel galenic formulations in which the active ingredient comprises one or more members selected from cyclic poly-N-methylated undecapeptides of the cyclosporin class - see e.g. GB patent publications nos. 2 222 770 A and 2 228 198 A and equivalents world-wide.
As discussed in the said GB patent publications, the cyclosporins present highly specific difficulties in relation to administration generally and galenic formulation in particular, including in 0 particular problems of drug bioavailability and variability in patient dose response.
In order to meet these and related difficulties, in GB patent publication no. 2 222 770 A, galenic formulations are disclosed comprising a cyclosporin as active ingredient and which take the form of, inter alia, a microemulsion or microemulsion pre-concentrate. Such compositions typically comprise 1) a hydrophilic phase, 2) a lipophilic phase and 3) a surfactant.
Specifically recited hydrophilic phase components are the products known and commercially available under the trade names Transcutol and Glycofurol as well as 1,2-propylene glycol. Preferred lipophilic phase components are medium chain fatty acid triglycerides such as known and commercially available under the trade names Miglyol, ' Captex, Myritol, Capmul, Captex, Neobee and Mazol, Miglyol 812 being the most preferred. ’ 7^662 of* Suitable surfactant components include, in particular, reaction products of natural or hydrogenated vegetable oils and ethylene glycol such as those known and commercially available under the trade names Cremophor and Nikkol, the products Cremophor RH40 and Nikkol HC0-40 being indicated as especially preferred.
GB patent publication no. 2 228 198 A proposes an alternative means for meeting difficulties in relation to cyclosporin administration. Specifically it discloses oil based formulations in which the oily component comprises a combination of tri-glyceride and (i) glycerol partial esters or (ii) 1,2-propylene glycol complete or partial esters or (iii) sorbitol complete or partial esters. The products known and commercially available under the tradename Maisine are proposed as suitable tri- and partial glyceride components. The disclosed compositions additionally comprise a surfactant component, for example Cremophor RH40, but are preferably free of any hydrophilic components such as ethanol. Described and exemplified compositions are free of such components.
In accordance with the present invention it has now surprisingly been found that particularly stable cyclosporin galenic formulations having particularly interesting bioavailability characteristics and reduced variability in inter- and intra-subject bioavailability parameters, are obtainable. Such compositions being new, the present invention provides in its broadest aspect: A pharmaceutical composition comprising a cyclosporin as active ingredient in a carrier medium comprising: 1) 1,2-propylene glycol; 2) a mixed mono-, di-, tri-glyceride; and 3) a surfactant.
The term pharmaceutical composition as used herein and in the - 3 accompanying claims is to be understood as defining compositions of which the individual components or ingredients are themselves pharmaceutically acceptable, e.g. where oral administration is foreseen, suitable or acceptable for oral application.
Cyclosporins to which the present invention applies are any of those having pharmaceutical utility, e.g. as immunosuppressive agents, anti-parasitic agents and agents for the reversal of multi-drug resistance, as known and described in the art, in particular Cyclosporin A (also known as and referred to hereinafter as Ciclosporin), Cyclosporin G, [0-(2-hydroxyethyl)-(D)Ser]8-Ciclosporin, and [ 3' -deshydroxy-3' -keto-MeBmt]1 - [ Val]2-Ciclosporin.
Components (2) in the compositions of the invention preferably comprise mixtures of C12-20 fatty acid mono-, di- and tri-glycerides, especially Ci6_18 fatty acid mono-, di- and triglycerides. The fatty acid component of said mixed mono-, di- and tri-glycerides may comprise both saturated and unsaturated fatty acid residues.
Preferably however they will predominantly be comprised of unsaturated fatty acid residues in particular, Cxe unsaturated fatty acid residues for example linolenic, linoleic and oleic acid residues. Suitably component (2) will comprise at least 60X, preferably at least 75X, more preferably 85X or more by weight C18 unsaturated fatty acid, e.g. linolenic, linoleic and oleic acid mono-, di- and tri-glycerides. Suitably they will comprise less than 20X, e.g. ca. 15X or 10X by weight or less, saturated fatty acid, e.g. palmitic and stearic acid mono-, di- and tri-glycerides.
Components (2) in the compositions of the invention will preferably be predominantly comprised of mono- and di-glycerides, e.g. comprise at least 50X, more preferably at least 70X, e.g. 75X, 80X, 85X by weight or more, mono- and di-glycerides, based on the total weight of component (2).
Components (2) in the compositions of the invention will suitably comprise from about 25 to about 50%, preferably from about 30 to about 40%, e.g. 35 to 40%, monoglycerides, based on the total veight of component (2).
Components (2) in the composition of the invention vill suitably comprise from about 30 to about 60%, preferably from about 40 to about 55%, e.g. about 48 to 50%, di-glycerides, based on the total veight of component (2).
Components (2) in the compositions of the invention vill suitably comprise at least 5%, e.g. from about 7.5 to about 15%, e.g. 9 to 12%, by veight of triglycerides.
Components (2) in the compositions of the invention may be prepared by admixture of individual mono-, di- or tri-glycerides in appropriate relative proportion. Conveniently however they will comprise transesterification products of vegetable oils, for example almond oil, ground nut oil, olive oil, peach oil, palm oil or, preferably, corn oil, sunflower oil or safflower oil and most preferably corn oil, with glycerol.
Such transesterification products are generally obtained by heating of the selected vegetable oil with glycerol, at high temperature in the presence of an appropriate catalyst under an inert atmosphere with continuous agitation, e.g. in a stainless steel reactor, to effect trans-esterification or glycerolysis. In addition to their mono-, diand tri-glyceride components, such transestrification products will also generally comprise minor amounts of free glycerol. The amount of free glycerol present in components (2) for use in the compositions of the invention will preferably be less than 10%, more preferably less than 5%, most preferably ca. 1 or 2% by weight based on the total weight of free glycerol plus mono-, di- and tri-glycerides. - 5 Preferably some of the glycerol is first removed e.g. by distillation (to give a substantially glycerol free batch), when soft gelatine capsules are to be made.
Especially suitable components (2) for use in the compositions of the invention will thus comprise the following components in the indicated amounts by weight based on the total weight of component (2): Mono-glycerides: 25 or 30 to 50%, especially 30 to 40%.
Di-glycerides: 30 or 40 to 60X, especially 40 to 55%, e.g. 45 to 55%. Mono- plus di-glycerides: >75%, especially >80%, e.g. ca. 85%. Tri-glycerides: at least 5%.
Free glycerol: <5%, preferably <2% or <1%.
Particularly suitable components (2) for use in the compositions of the invention are trans-esterification products of corn oil and glycerol, for example as commercially available under the trade name Maisine. Such products are comprised predominantly of linoleic and oleic acid mono-, di- and tri-glycerides together with minor amounts of palmitic and stearic acid mono-, di- and tri-glycerides (corn oil itself being comprised of ca. 56% by weight linoleic acid, 30% oleic acid, ca. 10% palmitic and ca. 3% stearic acid constituents).
Physical characteristics for Maisine [available from the company Etablissements Gattefosse, of 36, Chemin de Genas, P.O.Box 603, 69804 Saint-Priest, Cedex (France)] are: approximate composition free glycerol - 10% max. (typically 3.9-4.9% or, in substantially glycerol free batches, ca. 0.2%) - ca. 35% (typically 30-40% or, in substantially glycerol free batches, e.g. 32-36%, e.g. ca. 36%) mono-glycerides - 6 di-glycerides - ca. 50% (or, in substantially glycerol free batches ca. 46-48%) tri-glycerides - ca. 10% (or, in substantially glycerol free batches, ca. 12-15%) free oleic acid content - ca. 1% Further physical characteristics for Maisine are: acid value = max. ca. 2, iodine no. = ca. 85-105, saponification no. = ca. 150-175 (Fiedler Lexikon der Hilfsstoffe, 3rd revised and expanded edition (1989) Vol. 2, p.768). The fatty acid content for Maisine is typically: palmitic acid - ca. 11%; stearic acid - ca. 2.5%; oleic acid - ca. 29%; linoleic acid - ca. 56%; others - ca. 1.5%.
It is especially preferred that the component (2) e.g. a glycerol transesterified corn oil is clear, e.g. after keeping a sample in a refrigerator, e.g. between 2 and 8°C, for 24 hours, the sample is clear at room temperature 1 hour after taking the sample out of the refrigerator.
Preferably components (2) have a low saturated fatty acid content. Components (2) meeting these requirements may, for example be obtained from commercially available products, e.g. obtained therefrom by methods such as separative techniques as known in the art, e.g. freezing procedures coupled with separative techniques, e.g. centrifugation, to remove the saturated fatty acid components/enhance the unsaturated fatty acid component content. Typically the total saturated fatty acid component content will be <15%, e.g. <10%, or <5% by weight based on the total weight of component (2). A reduction of the content of saturated fatty acid component in the mono-glyceride fraction of components (2) may be observed after the separative technique. - 7 Components (2) thus preferably contain lesser quantities of saturated fatty acids (e.g. palmitic and stearic acids) and relatively greater quantities of unsaturated fatty acids (e.g. oleic and linoleic acids) than for the starting material.
Typical preferred components (2) may according to the preferred embodiment of this invention contain: 32-36% mono-glycerides, 45-55% di-glycerides and 12-20% tri-glycerides by weight based on the total weight of component (2).
Further preferred characteristics include the following: Fatty acid content as determined as the methyl ester by chromatography Methyl linoleate 53-63% Methyl oleate 24-34% Methyl linolenate 0- 3% Methyl arachate 0- 3% Methyl palmitate 6-12% Methyl stearate 1- 3% Relative Density 0.94-0.96 Hydroxyl Value 140-210 Iodine Value 110-120 Peroxide Value <4.0 Free Glycerol <1.0 Acid value max. ca. 2 Saponification no. ca. 150-185 Components (2) complying with the above outlined features are referred to hereafter as refined glycerol-transesterified corn oils. Freshly prepared components (2) according to the preferred embodiments are of clear appearance and stay clear at storage temperature of 20°C - 25°C for more than 20 days.
The refined glycerol-transesterified corn oils have especially been proposed for the preparation of the compositions of this invention. They may also have uses for the solubilization of other active agents and have the advantage of remaining stable, e.g. clear, for a long time. They constitute another aspect of present invention. The invention accordingly provides in another aspect a trans-esterification product of corn oil and glycerol comprising predominately of linoleic acid and oleic acid mono-, di- and tri-glycerides treated to enhance the unsaturated fatty acid component content of mono-, di- and tri-glycerides so that the linoleic acid and oleic acid mono-, di- and tri-glyceride content is in total 85% or more of the whole composition. This aspect of the invention forms the subject matter of a divisional application from the present application.
Components (3) in the compositions of the invention preferably have an HLB of at least 10.
Examples of suitable components (3) in the compositions of the invention are: 3.1 Reaction products of a natural or hydrogenated castor oil and ethylene oxide. Such products may be obtained in known manner, e.g. by reaction of a natural or hydrogenated castor oil with ethylene oxide, e.g. in a molar ratio of from about 1:35 to about 1:60, with optional removal of the polyethyleneglycol component from the product, e.g. in accordance with the methods disclosed in German Auslegeschriften 1,182,388 and 1,518,819.
Especially suitable are the various tensides available under the trade name Cremophor. Particularly suitable are the products Cremophor RH 40 having a saponification number of ca. 50-60, an acid number <1, an iodine number <1, a water content (Fischer) <2%, an nD60 of ca. 1,453 - 1,457 and an HLB of ca. 14 - 16; Cremophor RH 60 having a saponification number of ca. 40 - 50, an acid number <1, an iodine number <1, a water content (Fischer) 4.5-5.5%, and an nD25 of ca. 1.453-1.457 and an HLB of ca. 15-17; and Cremophor EL having a molecular weight (by steam osmometry) of ca. 1630, a saponification number of ca. 65-70, an acid number of ca. 2, an iodine number of ca. 28-32 and an nD25 of ca. 1.471. (c.f.
Fiedler, Lexikon der Hilfstoffe, 3rd revised and expanded edition (1989), Vol.1,p.326). Also suitable for use in this category are the various tensides available under the trade marks Nikkol (e.g. Nikkol HCO-40 and HCO-60), Emulgin (e.g.
Emulgin R040), Mapeg (e.g. Mapeg C0-40h) and Incrocas (e.g.
Incrocas 40) (c.f. Fiedler). The said product Nikkol HCO-60 is a reaction product of hydrogenated castor oil and ethylene oxide exhibiting the following characteristics: acid value ca. 0.3; saponification number of ca. 47.4; hydroxy value of ca. 42.5; pH (5%) of ca. 4.6; color APHA = ca. 40; m.p. = ca. 36.0°C; freezing point = ca. 32.4°C; H20 content (%, KF) = 0.03. 3.2 Polyoxyethylene-sorbitan-fatty acid esters, e.g. mono- and tri-lauryl, palmityl, stearyl and oleyl esters, e.g. of the type known and commercially available under the trade mark Tween (cf. Fiedler, loc.cit. p.1300-1304) including the products Tween [polyoxyethylene (20) sorbitanmonolaurate) , [polyoxyethylene(4)sorbitanmonolaurate), [polyoxyethylene (20) sorbitanmonopalmitate] , [polyoxyethylene(20)sorbitanmonostearate], * [polyoxyethylene(20)sorbitantristearate], [polyoxyethylene (20)sorbitanmonooleate] , * [polyoxyethylene (5)sorbitanmonooleate), [polyoxyethylene(20)sorbitantrioleate).
Especially preferred products of this class for use in the compositions of the invention are the above products Tween 40 and Tween 80. 3.3 Polyoxyethylene fatty acid esters, for example polyoxyethylene stearic acid esters of the type known and commercially available under the trade mark Myrj (c.f. Fiedler, loc. cit., 2, p. 834835) ; an especially preferred product of this class for use in 0 the compositions of the invention is the product Myrj 52 having a D25= ca. 1.1., m.p. = ca. 40-44°C, an HLB value = ca. 16.9., an acid value = ca. 0-1 and a saponification no. = ca. 25-35. 3.4 Polyoxyethylene-polyoxypropylene co-polymers and block co-polymers, e.g. of the type known and commercially available under the trade marks Pluronic, Emkalyx and Poloxamer (c.f. Fiedler, loc. cit., 2., p. 959). An especially preferred product of this class for use in the compositions of the invention is the product Pluronic F68, having an m.p. = ca. 52°C and a molecular weight of ca. 6800-8975. A further preferred product of this class for use in the compositions of the invention is the product Poloxamer 188. 3.5 Dioctylsulfosuccinate or di-[2-ethylhexyl]-succinate (c.f. Fiedler, loc. cit., 1., p. 107-108). 3.6 Phospholipids, in particular lecithins (c.f. Fiedler, loc. cit., .2, p. 943-944) . Lecithins suitable for use in the compositions of the invention include, in particular, soya bean lecithins. 3.7 Propylene glycol mono- and di-fatty acid esters such as propylene glycol dicaprylate (also known and commercially available under the trade mark Miglyol 840), propylene glycol dilaurate, propylene glycol hydroxystearate, propylene glycol isostearate, propylene glycol laurate, propylene glycol ricinoleate, propylene glycol stearate and so forth (c.f. Fiedler, loc. cit., 2_, p. 808-809). 3.8 Sodium lauryl sulfate.
For use in relation to the present invention, components as set out under (3.1) above are most preferred.
Components (1), (2) and (3) are preferably present in the compositions of the invention in relative proportions such that the composition is a micro-emulsion preconcentrate, i.e. having the characteristics of a micro-emulsion preconcentrate system as described in GB patent publication no. 2 222 770 A at pages 11 to 12. Compositions of the invention are thus preferably microemulsion preconcentrates, in particular of the type providing o/w (oil-in-water) microemulsions. The present invention is also to be understood as including compositions comprising components (1), (2) and (3) together with (4) water and which are microemulsions.
As also indicated in GB patent publication no. 2 222 770 A the hydrophilic phase of microemulsion preconcentrate systems, i.e. component (1) in compositions of the present invention may include one or more additional ingredients as hydrophilic phase component, for example lower (e.g. Cj.j) alkanols, in particular ethanol. Such components will generally be present in partial replacement of component (1) . While the use of ethanol in compositions of the present invention is not essential, it has been found to be of particular advantage when the compositions are to be manufactured in soft gelatine encapsulated form, e.g. as a means of improving storage characteristics, in particular to reduce risk of cyclosporin precipitation following encapsulation procedures. Thus the shelf 11a life stability may be extended by employing a lower alkanol as an additional ingredient of the hydrophilic phase.
Suitably the hydrophilic phase component, i.e. component (1), - 12 1,2-propylene glycol, or component (1) plus any hydrophilic phase co-component(s), e.g. ethanol, will be present in the compositions of the invention in an amount of from 1.0 or 2.5 to 50%, preferably from 5 to 40%, more preferably from 10 to 35%, e.g. above 15%, e.g. from about 20 to about 30% by weight based on the total weight of hydrophilic phase component(s) plus components (2) and (3).
When a hydrophilic phase co-component is employed, the co-component, e.g. ethanol, is suitably present in an amount of up to about 20%, preferably up to about 10 or 15%, e.g. from about 5 to 10 or 15% by weight based in the total weight of the composition. Such co-component is thus suitably present in an amount of from about 25 to 75% by weight based on the total weight of hydrophilic phase components (e.g. 1,2-propylene glycol plus ethanol) more preferably it is present in an amount of less than 50%, e.g. from 25 to 50%, for example about 30, 40 or 50%.
Suitably component (2) will be present in the compositions of the invention in an amount of from 5 to 65%, preferably from 15 to 45%, more preferably from 20 to 40%, e.g. from about 25 to about 35%, based on the total weight of hydrophilic phase component(s) plus components (2) and (3).
Suitably component (3) will be present in the compositions of the invention in an amount of from 25 to 75%, preferably from 30 to 60%, e.g. from about 55 or 60% based on the total weight of hydrophilic phase component(s) plus components (2) and (3).
Suitably the compositions of the invention will comprise from about 1 or 2 to 30%, preferably from 5 to 20 or 25%, more preferably from 7.5 to 15%, e.g. about 10% by weight of cyclosporin based on the total weight of the composition.
Accompanying Figure I represents a three-way plot for relative concentrations of hydrophilic phase component, i.e. 1,2-propylene glycol, component (2), e.g. refined glycerol-transesterified corn oil, and component (3), e.g. Cremophor RH40, in compositions in accordance with the invention and comprising 10% cyclosporin (e.g. Ciclosporin) by weight. Relative concentrations of the carrier components increase in the directions indicated by the arrows from 0 to 100%.
For compositions in accordance with the present invention the relative proportion of hydrophilic phase component(s), component (2) and component (3) will suitably lie within the shaded area X. Compositions thus defined are microemulsion preconcentrates of high stability, capable on addition to water, of providing microemulsions having an average particle size of In the event that the 1,2-propylene glycol component is partially replaced by ethanol as hereinbefore described, the area X of Fig. I is shifted slightly upwards within the plot, i.e. in the direction of higher component (3) concentration. This shift however represents an upwards displacement of a few percent only and does not substantially alter the obtained plot.
The compositions of the invention show good stability characteristics, e.g. as indicated by standard stability trials, e.g. having a shelf life stability of up to three years, and even longer.
Compositions in accordance with the present invention may also include further additives or ingredients, for example [e.g. antioxidants ascorbyl palmitate, butyl hydroxy anisole (BHA), butyl hydroxy toluene (BHT) and tocopherols, e.g. α-tocopherol (vitamin E)] and/or preserving agents, e.g. in an amount of from about 0.05 to 1% by weight based on the total weight of the composition, or sweetening or flavoring agents, e.g. in an amount of up to about 2.5 or 5% by weight based on the total weight of the composition.
Compositions in accordance with the present invention have been found to exhibit especially advantageous properties when administered orally, e.g. in terms of both the consistency and high level of 1q bioavailability achieved as indicated in standard bioavailability trials e.g. in healthy patients using a specific monoclonal kit to determine cyclosporin levels, e.g. as described in the Examples hereinafter. In particular the compositions in accordance with the present invention provide an improved oral administration form for Ί 5 cyclosporins (e.g. Ciclosporin) as it exhibits absence of significant food interaction, which we have observed with the commercially available oral form of Ciclosporin especially with fat rich food. Moreover, inter-subject and intra-subject variability of pharmacokinetic parameters may be significantly lower with the 2Q compositions according to the present invention than with the commercial oral form of Ciclosporin. Specifically the difference between the pharmacokinetic parameters with food intake and without food intake, or even between day time absorption and night time absorption, may be eliminated by administering the composition in accordance with the present invention. Thus with the novel composition according to present invention the pharmacokinetic parameters, e.g. absorption and blood levels, become surprisingly more predictable and this new galenic form may eliminate problems in administration with erratic absorption of Ciclosporin. Additionally the composition according to present invention, may exhibit an improved bioavailability in patients having malabsorption, e.g. liver transplantation patients or pediatric patients. In particular it has been found that such compositions are compatible with tenside - 15 materials, e.g bile salts, present in the gastro-intestinal tract.
That is, they are fully dispersible in aqueous systems comprising such natural tensides and are thus capable of providing microemulsion systems in situ which are stable and do not exhibit precipitation of the cyclosporin or other disruption of fine particulate structure. Function of such systems on oral administration remains independent of and/or unimpaired by the relative presence or absence of bile salts at any particular time or for any given individual.
The compositions of the invention are well tolerated, e.g. as indicated by clinical trials over 4 weeks.
Compositions in accordance with the present invention will preferably be compounded in unit dosage form, e.g. by filling into orally administerable capsule shells, e.g. soft or hard gelatine capsule shells but if desired may be in drink, solution form. Where compositions are in unit dosage form, each unit dosage will suitably contain between 10 and 200 mg cyclosporin, more suitably between 10 and 150 mg, e.g. 15, 20, 25, 50 or 100 mg cyclosporin. Such unit dosage forms are suitable for administration lx, 2x or 3x up to 5x daily (e.g. depending on the particular purpose of therapy, the phase of therapy etc.).
Alternatively compositions in accordance with the present invention suitable for oral administration may include (4) water or any other aqueous system, to provide microemulsion systems suitable for drinking.
In addition to the foregoing the present invention also provides a process for the production of a pharmaceutical composition as hereinbefore defined, which process comprises bringing a component (1), a component (2) and a component (3) as hereinbefore defined into intimate admixture and, when required compounding the obtained composition in unit dosage form, for example filing said composition into gelatine, e.g. soft or hard gelatine, capsules.
In a more particular embodiment the present invention provides a process for the production of a pharmaceutical composition as hereinbefore defined in the form of a microemulsion preconcentrate or microemulsion, which method comprises bringing a component (1), a component (2) and a component (3), optionally together with further components or additives, in particular with a hydrophilic phase co-component, for example ethanol, into intimate admixture in relative proportions of components (1), (2) and (3), such that a microemulsion preconcentrate is obtained and, when required, compounding the obtained composition in unit dosage form or combining said obtained composition with sufficient water or sufficient of an aqueous solvent medium such that a microemulsion is obtained.
The following examples are illustrative of compositions in accordance with the invention, in unit dosage form, suitable for use, e.g. in the prevention of transplant rejection or for the treatment of autoimmune disease, on administration of from 1 to 5 unit dosages/day. The examples are described with particular reference to Ciclosporin. However equivalent compositions may be obtained employing any other cyclosporin, in particular [0-(2-hydroxyethyl)-(D)-Ser]8-Ciclosporin (hereinafter referred to as Compound Z).
EXAMPLE 1: Preparation of refined glycerol-transesterified corn oil.
Substantially-glycerol free glycerol-transesterified corn oil (if necessary after heating to give a clear mixture) is slowly cooled to a temperature of +20°C and kept at this temperature for one night. In a first-step centrifugation, at an acceleration of 12 000 G and a flow rate of 103 kg/h in a continuous flow centrifuge, a liquid phase (62 kg/h) and a sediment-containing phase (41 kg/h) are obtained. The liquid phase is slowly cooled to +8°C and kept at this temperature for one night. In a second-step centrifugation at an acceleration of 12 000 G and a flow rate of 112 kg/h a liquid phase (76.2 kg/h) and a sediment-containing phase (35.8 kg/h) are obtained. The liquid phase is refined glycerol-transesterified corn oil. Alternatively an improved product may be obtained by effecting the centrifugation in three steps, e.g. at +2O°C, +10°C and +5°C.
The process is characterised by a slight percentage reduction in the mono-glyceride component in the refined glycerol transesterified corn oil as compared to the starting material (e.g. 35.6% compared to 38.3%).
A typical analytical comparison between the sediment and clear solution is as follows: Compound Sediment (Z) Clear Solution 1. Mono palmitate 19.1 3.4 2. Mono linoleate + 23.4 27.0 Mono oleate 3. Mono stearate 5.7 <2 4. Dilinoleate + 35.4 44.7 Dioleate 5. Other di-glycerides 7.7 10.4 6. Tri-glycerides 8.7 12.5 Typical contents of components in the refined product obtained from these preparations are listed in the following Table: COMPOSITION OF COMPONENTS (% v/v) Components refined glycerol-trans- esterified corn oil Glycerides: mono 33.3 di 52.1 tri 14.6 Fatty acids: palmitic acid (C16) 7.8 stearic acid (C18) 1.7 oleic acid (C18:l) 31.6 linoleic acid (C18:2) 57.7 Glycerol content <1% EXAMPLE 2: Preparation of oral unit dosage forms COMPONENT QUANTITY (mg/capsule) Cyclosporin, e.g. Ciclosporin 100 1) 1,2-propylene glycol 200 2) refined oil 320 3) Cremophor RH40 380 Total 1,000 The cyclosporin is dissolved in (1) with stirring at room temperature and (2) and (3) are added to the obtained solution again with stirring. The obtained mixture is filled into size 1 hard gelatine capsules and sealed e.g. using the Quali-Seal technique.
Compositions comprising 50 and 100 mg Ciclosporin, are prepared 5 analogously employing the following indicated ingredients in the indicated amounts.
In this Example, refined oil = refined glycerol-transesterified corn oil as described in Example 1 or Maisine, e.g. substantially glycerol free Maisine. 0 COMPOSITIONS COMPRISING 100 mg cyclosporin, e.g. Ciclosporin COMPOSITION — 2 3 _ _ 5 _ 1 6 COMPONENT QUANTITY (mg/capsule) 1) 1,2-Propylene glycol 200 270 180 180 90 2) refined oil 350 180 180 360 360 3) Cremophor RH40 350 450 540 360 450 _ I I I I I I j COMPOSITION I 7 _ 8 1 9 J 10 1 |COMPONENT I QUANTITY (mg/capsule) 1 |1) 1,2-Propylene glycol 150 100 1 j 200 I 200 1 |la) ethanol I 100 100 ί 100 100 • 20 1 |2) refined oil I 345 320 j 320 j 290 1 |3) Cremophor RH40 1 405 380 _ j 380 J 360 COMPOSITIONS COMPRISING 50 mg Ciclosporin I-1-1 I-1 I-1-1 1 COMPOSITION I A B 1 c j D _ E F 1 1 COMPONENT I QUANTITY (mg/capsule) 1 |1) 1,2-Propylene glycol I 100 135 ί *5 J_ 90 100 50 1 |la) ethanol 1 1 1 1 50 1 |2) refined oil 160 90 ί 180 180 67 160 |3) Cremophor RH40 1 190 225 1 225 J_ 180 167 190 _ As indicated above equivalent compositions may be made containing Compound Z instead of Ciclosporin. Thus composition D may be made containing 50 mg Compound Z instead of Ciclosporin.
EXAMPLE 3: Bioavailability in dogs The biopharmaceutical properties of compositions in accordance with the present invention we compared with the marketed soft-gelatine capsule of Ciclosporin. The forms were compared after oral administration to 12 male beagle dogs in a cross-over design. The pharmacokinetic profile of Ciclosporin was determined in whole blood over 24 hours, the areas under the curve of the blood concentration versus time curves (AUC), Cmax and Tmax were determined.
Forms: Dose 100 mg Ciclosporin/dog 21' Composition X (commercial form, soft gelatin capsule) Ciclosporin 100 mg Labrafil (trade mark) 300 mg ethanol 100 mg 5 Maize oil 416 mg Total 926 mg/dosage Composition I according to present invention (a soft gelatin capsule): Ciclosporin 100 mg 0 1) 1, 2-propylene glycol 75 mg la) ethanol 150 mg 2) refined glycerol-transesterified corn oil 345 mg 3) Cremophor RH4 0 405 mg Total 1075 mg/dosage Drug administration: male beagle dogs weighing around 12 kg completed the trial successfully. Twenty hours before the drug administration the food was withdrawn but the animals were allowed free access to water until the beginning of the experiment. The dosage forms were administered by gavage to the animals, early in the morning (approx. 8.00 am), and followed by 20 ml NaCl 0.9% solution. Three hours after the administration, the animals were again allowed free access to water and food. A 1 week wash-out period was necessary between 2 administrations to the same animal.
I - 22 Blood sampling: Blood samples of 2 ml (or 5 ml for the blank sample) were taken from the vena cephalica (forearm) with a sterile needle (diameter ca. 1.2 mm) and collected into 5 ml plastic tubes containing EDTA at -15 min, 30 min, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours after the oral administration of the drug. The blood samples were stored at ca. -18°C until drug assay. The blood samples were analysed by Ciclosporin-specific radioimmunoassay (RIA). The median blood concentrations of Ciclosporin in dogs are plotted in the accompanying Figure II. The areas under the blood drug concentration versus time curves (AUC) were calculated using the trapezoidal rule. An analysis (CV) of variance was performed and the mean AUCs, Cmax and Tmax were compared statistically by the Tukey test. The results obtained are shown in the following table.
Composition AUC 0-24 h Cmax Mean [ng/ml] T Ama x Mean [ng.h/ml] CV [%] CV [%] Mean [h] CV [%1 X 6695 27 1053 25 1.3 20 I 10064 24 1539 18 1.6 29 The behaviour and body weight of the animals were controlled during the study. No body weight loss could be detected.
Conclusion: The composition according to the present invention (composition I) has a significantly higher bioavailability (factor 1.5) than the commercial soft-gelatin capsule of Ciclosporin.
Figure II shows the average whole blood Ciclosporin concentrations as determined by a specific monoclonal RIA following single oral administration of Composition X and Composition I each in 100 mg dosage. Blood concentration (in ng/ml) is recorded vertically and time - 23 horizontally.
EXAMPLE 4: Bioavailability in humans The bioavailability of Ciclosporin is compared as it is determinable after administration of the commercial Ciclosporin soft gelatine capsule and of a composition according to present invention.
Administered form: 100 mg Ciclosporin per capsule Composition X (commercial form, soft gelatine capsule) Ciclosporin 100 mg Labrafil 300 mg 0 Ethanol 100 mg Maize oil 426 mg Total 926 mg/Capsule Composition No. 8 (according to Example 2 containing refined glycerol-transesterified corn oil) in a soft gelatine capsule.
Method: Forty eight healthy male subjects completed the study. Each of the participants received four of the eight administrations (two doses of composition 8 and the same two doses of composition X).
The participants were randomly allocated to two subgroups consisting 20 of twenty four subjects each according to a parallel design. Subjects in Group I received doses of 200 mg and 600 mg Ciclosporin and subjects in Group II received 400 mg and 800 mg. - 24 Within each of the two groups the trial was conducted on the basis of a balanced 4-way cross-over design with a wash-out period of two weeks " between each treatment.
Blood samples for determination of Ciclosporin in whole blood were 5 taken 1 minute before drug intake and then 15 min, 30 min. 45 min, h, 1.5h, 2 h, 2.5 h, 3 h, 3.5 h, 4 h, 4.5 h, 5 h, 6 h, 8 h, 20 h, h, 16 h, 20 h, 24 h, 28 h, 32 h, 36 h, 40 h, and 48 h after drug intake.
The individual concentrations of Ciclosporin in whole blood were determined for each blood sample by a specific RIA-method.
The limit of quantification was 12.5 ng/ml.
Blood concentrations and corresponding AUC(o_48 h)-values of Ciclosporin were significantly higher after administration of Composition 8 than after administration of Composition X at all dosage strengths. Peak concentrations (Cnax) of the 200 mg, 400 mg, and 600 mg dose levels appeared somewhat earlier after administration of Composition 8 (see following table). - 25 Table: Bioavailability of Ciclosporin in Humans Mean (+SD) values of AUC(0_48 hi , Cmax and Tmax after single J oral administration Composition 8 of different dosages of Composition X and 5 Form AUC(o-48 h) Cmax Tnax [ng.h/ml] [ng/ml] [h] 200 mg Comp X 200 mg Comp 8 2028 ± 3468 ± 608 1000 558 ± 228 2.1 ± 0.7 1025 ± 218 1.5 ± 0.4 400 mg Comp X 3326 ± 1115 785 + 252 2.1 + 0.9 400 mg Comp 8 6944 + 1468 1557 ± 286 1.4 ± 0.4 600 mg Comp X 4501 ± 1217 917 ± 236 2.3 ± 1.0 600 mg Comp 8 9689 ± 2282 1812 ± 400 1.7 ± 0.6 800 mg Comp X 5209 ± 1554 1045 ± 264 2.4 ± 1.0 800 mg Comp 8 12162 ± 3059 2143 + 576 2.1 ± 0.8 Based on the mean ratios of AUC (o-48 h)~values the relative bioavailability of Composition 8 vs Composition X was estimated between 170% and 233%, depending on the dose administered (see following table).
Table: Relative bioavailability of Composition 8 vs. Composition X Dose of [mg] Mean ratio of AUC(0-48 h) Comp 8 vs. Comp X Conversion Factor: Comp X vs. Comp 8 200 1.70 0.59 400 2.09 0.48 600 2.15 0.47 800 2.33 0.43 - 26 Conclusion: The composition according to the present invention (Composition 8) has a significantly higher bioavailability in humans be at least factor 1.7 when compared to the commercial form (Composition X).
The accompanying Figure III provides a graphical plot of the mean AUC(o_4β hi - values of composition X (open triangles) versus those of Composition 8 (solid Circles). AUC-values (in ng.h/ml) of Ciclosporin vertically and dose horizontally as obtained from Example 4.
The extent of absorption of Composition 8 (in terms of 10 AUC(o — 4β hi-values) seemed to be independent of dose, whereas the extent of absorption of Composition X declined with increasing doses (see Figure III).
Claims (23)
1. A pharmaceutical composition comprising a cyclosporin as active ingredient in a carrier medium comprising: 1) 1,2-propylene glycol 2. ) a mixed mono-, di-, tri-glyceride, and 3. ) a surfactant.
2. A composition according to claim 1, wherein component (2) comprises C 12 -C 20 fatty acid mono-, di- and tri-glycerides.
3. A composition according to claim 2, wherein component (2) comprises linolenic, linoleic and oleic acids.
4. A composition according to claim 2 or 3, wherein component (2) comprises a trans-esterification product of a vegetable oil.
5. A composition according to claim 4, wherein the vegetable oil is corn oil.
6. A composition according to claim 4 or 5, wherein the vegetable oil is transesterified with glycerol.
7. A composition according to any one of claims 2 to 6, wherein the free glycerol content is below 1%.
8. A composition according to claim 6 or 7 wherein component (2) comprises Maisine.
9. A composition according to claim 6 or 7 wherein component (2) comprises a refined glycerol-transesterified corn oil.
10. A composition according to claim 9 wherein component (2) comprises a composition according to any preceding claim which is a trans-esterification product of corn oil and glycerol comprising predominately of linoleic acid and oleic acid mono-, di- and tri-glycerides treated to enhance the unsaturated fatty acid component content of mono-, di- and tri-glycerides so that the linoleic acid and oleic acid mono-, di- and tri-glyceride content is in total 85% or more of the whole composition.
11. A composition according to any preceding claim wherein component (2) comprises from about 30% to about 40% mono-glycerides, from about 45% to about 55% of di-glycerides and at least 5% of tri-glycerides by weight based on the total weight of component (2).
12. A composition according to claim 11 wherein component (2) comprises from about 32% to about 36% of mono-glycerides, from about 45% to about 55% of di-glycerides, and from about 12% to about 20% of tri-glycerides by weight based on the total weight of component (2).
13. A composition according to any preceding claim, wherein component (3) has an HLB value of at least 10.
14. A composition according to any one of claims 1 to 13, wherein component (3) comprises a reaction product of a natural or hydrogenated castor oil and ethylene oxide.
15. A composition according to any preceding claim, wherein (3) comprises Cremophor RH40.
16. A composition according to any preceding claim wherein the carrier medium additionally comprises a hydrophilic phase co-component.
17. A composition according to claim 16 wherein the hydrophilic phase - 29 co-component is ethanol. *
18. A composition according to any preceding claim which is a j micro-emulsion preconcentrate.
19. A composition according to any preceding claim in unit dosage 5 form.
20. A composition according to claim 19, comprising a gelatine encapsulated form.
21. A composition according to any preceding claim additionally comprising water or an aqueous phase and which is a microemulsion. 10
22. A composition according to any preceding claim, wherein component (1) plus any hydrophilic phase co-component present comprises from 10 to 35% by weight of the hydrophilic phase component (1) plus components (2) and (3).
23. A composition according to claim 22, wherein the hydrophilic phase 1 5 co-component is present in an amount of from about 25 to 75% of the total weight of component (3) and the hydrophilic phase co-component. A composition according to any preceding claim, wherein component (2) is present in an amount of from 20 to 40% the total weight of hydrophilic phase component(s) plus (2) and (3). the based on component 25. A composition according to any preceding claim, wherein the component (3) is present in an amount of from 30 to 60% based on the total weight of hydrophilic phase component(s) plus component (2) and (3). 26. 27. 5 28. 29. 0 30. 31. A composition according to any preceding claim containing from 7.5 to 15% by weight of cyclosporin. A composition according to any preceding claim containing Ciclosporin as the cyclosporin. A composition according to any one of claims 1 to 26 containing [0-(2-hydroxyethyl )-(D)Ser]’-Ciclosporin as the cyclosporin. A composition according to any one of claims 1 to 26 containing [3 ' -deshydroxy-3 ' -keto-MeBmt] x - [Val] 2 -Ciclosporin as the cyclosporin. A composition according to any one of claims 1 to 26 containing Cyclosporin G as the cyclosporin. A composition according to claim 1 substantially as hereinbefore described with reference to any one of the Examples .
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB919113872A GB9113872D0 (en) | 1991-06-27 | 1991-06-27 | Improvements in or relating to organic compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
IE922082A1 IE922082A1 (en) | 1992-12-30 |
IE73662B1 true IE73662B1 (en) | 1997-06-18 |
Family
ID=10697415
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IE922082A IE73662B1 (en) | 1991-06-27 | 1992-07-01 | Cyclosporin compositions for oral administration |
Country Status (38)
Country | Link |
---|---|
EP (2) | EP0539319B1 (en) |
JP (2) | JP2653958B2 (en) |
KR (3) | KR0131064B1 (en) |
CN (1) | CN1077798C (en) |
AT (1) | AT403436B (en) |
AU (1) | AU659460B2 (en) |
CA (2) | CA2175842C (en) |
CH (2) | CH684163A5 (en) |
CY (1) | CY1906A (en) |
CZ (1) | CZ281790B6 (en) |
DE (3) | DE4219526C2 (en) |
DK (2) | DK0953630T3 (en) |
EE (1) | EE03108B1 (en) |
ES (2) | ES2227921T3 (en) |
FI (2) | FI109454B (en) |
FR (2) | FR2678169B1 (en) |
GB (2) | GB9113872D0 (en) |
GR (1) | GR3032366T3 (en) |
HK (2) | HK57196A (en) |
HU (1) | HU216792B (en) |
IE (1) | IE73662B1 (en) |
IL (3) | IL118546A (en) |
IT (1) | IT1254401B (en) |
LU (1) | LU88138A1 (en) |
MX (1) | MX9203236A (en) |
MY (1) | MY109512A (en) |
NO (2) | NO303964B1 (en) |
NZ (1) | NZ243309A (en) |
PH (1) | PH30337A (en) |
PT (2) | PT953630E (en) |
RO (2) | RO111021B1 (en) |
RU (1) | RU2143919C1 (en) |
SA (1) | SA92130213B1 (en) |
SK (1) | SK278759B6 (en) |
TW (1) | TW267943B (en) |
UA (1) | UA35559C2 (en) |
UY (1) | UY23864A1 (en) |
ZA (1) | ZA924719B (en) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9113872D0 (en) * | 1991-06-27 | 1991-08-14 | Sandoz Ag | Improvements in or relating to organic compounds |
EP0589843B1 (en) * | 1992-09-25 | 2001-11-28 | Novartis AG | Pharmaceutical compositions containing cyclosporins |
NZ247516A (en) * | 1993-04-28 | 1995-02-24 | Bernard Charles Sherman | Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant |
AT408520B (en) * | 1993-05-27 | 2001-12-27 | Novartis Erfind Verwalt Gmbh | Pharmaceutical formulations |
GB2278780B (en) * | 1993-05-27 | 1998-10-14 | Sandoz Ltd | Macrolide formulations |
CH686761A5 (en) | 1993-05-27 | 1996-06-28 | Sandoz Ag | Pharmaceutical formulations. |
EP0649651B1 (en) * | 1993-09-28 | 2000-12-13 | R.P. Scherer GmbH | Soft gelatin capsule manufacture |
DE4340781C3 (en) * | 1993-11-30 | 2000-01-27 | Novartis Ag | Liquid preparations containing cyclosporin and process for their preparation |
US5891846A (en) * | 1994-02-17 | 1999-04-06 | Shiseido Company, Ltd. | Cyclosporin-containing emulsion composition |
EP0694308A4 (en) * | 1994-02-17 | 1997-09-10 | Shiseido Co Ltd | Cyclosporin-containing emulsion composition |
NZ270145A (en) * | 1994-03-01 | 1996-08-27 | Lilly Co Eli | Non-aqueous pharmaceutical formulation for oral administration comprising water-insoluble active agent, fatty acid solubilising agent, an oil and a surface active agent |
GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
DE69510404T2 (en) * | 1994-03-31 | 2000-01-20 | Loders Croklaan Bv | Oils with a low saturated fatty acid content |
IL129547A (en) * | 1994-10-26 | 2001-01-11 | Novartis Ag | Pharmaceutical compositions comprising a macrolide and an acid |
GB2308545B (en) * | 1994-10-26 | 1999-06-02 | Novartis Ag | Pharmaceutical microemulsion preconcentrates |
RU2158601C2 (en) | 1994-11-03 | 2000-11-10 | Новартис Аг | Novel medicinal forms of cyclosporine for oral administration having simple formulation and bioavailability, and method of preparation thereof |
HU215966B (en) * | 1994-11-21 | 1999-07-28 | BIOGAL Gyógyszergyár Rt. | Oral multiple emulsion-preconcentrate containing cyclosporin |
US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
WO1996036330A2 (en) * | 1995-05-17 | 1996-11-21 | Cedars-Sinai Medical Center | Compositions containing fatty acids for improving digestion and absorption in the small intestine |
US6861053B1 (en) | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
KR19990014865A (en) * | 1995-05-17 | 1999-02-25 | 피터 이. 브래이브맨 | Compositions containing fatty acids to enhance digestion and absorption in the small intestine |
US6008228A (en) * | 1995-06-06 | 1999-12-28 | Hoffman-La Roche Inc. | Pharmaceutical compositions containing proteinase inhibitors |
US6696413B2 (en) * | 1995-06-16 | 2004-02-24 | Hexal Ag | Pharmaceutical preparation with cyclosporin A |
SE504582C2 (en) * | 1995-07-06 | 1997-03-10 | Gs Dev Ab | Cyclosporin composition based on an L2 phase |
DE19549852B4 (en) * | 1995-11-29 | 2009-06-04 | Novartis Ag | Cyclosporin containing preparations |
US5858401A (en) | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
CN1104258C (en) * | 1996-05-29 | 2003-04-02 | 周德和 | Special-used water-solubility (hydrophilicity) excipient for difficult-soluble medicine |
RU2181055C2 (en) * | 1996-06-19 | 2002-04-10 | Новартис Аг | Cyclosporine-containing preparation as capsule with soft cover |
US5958876A (en) * | 1996-06-19 | 1999-09-28 | Novartis Ag | Cyclosporin-containing pharmaceutical compositions |
KR980008239A (en) * | 1996-07-26 | 1998-04-30 | 김충환 | Cyclosporin-containing pharmaceutical composition |
FR2752732B1 (en) * | 1996-08-28 | 1998-11-20 | Pf Medicament | EXTENDED RELEASE GALENIC FORM OF MILNACIPRAN |
US6517860B1 (en) | 1996-12-31 | 2003-02-11 | Quadrant Holdings Cambridge, Ltd. | Methods and compositions for improved bioavailability of bioactive agents for mucosal delivery |
HU228855B1 (en) * | 1997-03-12 | 2013-06-28 | Abbott Lab | Hydrophilic binary systems for the administration of cyclosporine |
US6258783B1 (en) | 1997-04-29 | 2001-07-10 | Bernard Charles Sherman | Emulsion preconcentrate comprising a cyclosporin and acetylated monoglyceride |
NZ314702A (en) * | 1997-04-29 | 1998-07-28 | Bernard Charles Sherman | Pharmaceutical composition comprising a cyclosporin in a solvent system of acetylated monoglycerides and a surfactant and optionally a hydrophilic solvent |
GB2326337A (en) | 1997-06-20 | 1998-12-23 | Phares Pharma Holland | Homogeneous lipid compositions for drug delivery |
ES2219895T3 (en) * | 1997-07-29 | 2004-12-01 | PHARMACIA & UPJOHN COMPANY | SELF-EMULSIONING FORMULATION FOR LIPOFILOS COMPOUNDS. |
DK0989851T3 (en) | 1997-07-29 | 2003-01-27 | Upjohn Co | Self-emulsifying formulation containing acidic lipophilic compounds |
CN1113650C (en) | 1997-07-29 | 2003-07-09 | 法玛西雅厄普约翰美国公司 | Self-emulsifying formulation forlipophilic compounds |
AU748334B2 (en) | 1997-10-16 | 2002-05-30 | Board Of Regents, The University Of Texas System | Models and treatments for cardiac hypertrophy in relation with NF-AT3 function |
AU1508899A (en) * | 1997-12-02 | 1999-06-16 | Chong Kun Dang Corporation | Pharmaceutical composition comprising cyclosporin solid-state microemulsion |
JP4761093B2 (en) | 1997-12-10 | 2011-08-31 | シクロスポリン セラポイティクス リミテッド | Pharmaceutical composition comprising omega-3 fatty acid oil |
ID25908A (en) * | 1998-03-06 | 2000-11-09 | Novartis Ag | EMULSION PRACTONCENTRATES CONTAINING CYCLOSPORINE OR MACROLIDES |
ES2215277T3 (en) * | 1998-08-18 | 2004-10-01 | Panacea Biotec Limited | CYCLOSPORINE COMPOSITION THAT INCLUDES A HYDROPHYLE VEHICLE. |
GB9903547D0 (en) | 1999-02-16 | 1999-04-07 | Novartis Ag | Organic compounds |
CN1167462C (en) * | 1999-03-09 | 2004-09-22 | 杭州华东医药集团生物工程研究所有限公司 | Medicinal composition containing cyclosporin |
US6956048B2 (en) | 1999-03-31 | 2005-10-18 | Pharmacia & Upjohn Company | Pharmaceutical emulsions for retroviral protease inhibitors |
WO2001032143A1 (en) * | 1999-11-02 | 2001-05-10 | Cipla Ltd. | A pharmaceutical composition for the administration of water-insoluble pharmaceutically active substances and a process for preparation thereof |
US7732404B2 (en) | 1999-12-30 | 2010-06-08 | Dexcel Ltd | Pro-nanodispersion for the delivery of cyclosporin |
GB0008785D0 (en) | 2000-04-10 | 2000-05-31 | Novartis Ag | Organic compounds |
US7008661B2 (en) | 2000-08-08 | 2006-03-07 | Kao Corporation | Oil/fat composition |
US7115565B2 (en) | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
KR100982466B1 (en) | 2001-10-19 | 2010-09-16 | 이소테크니카 인코포레이티드 | Synthesis of cyclosporin analogs |
KR100441167B1 (en) * | 2001-12-27 | 2004-07-21 | 씨제이 주식회사 | Composition of microemulsion preconcentrate |
KR100525234B1 (en) * | 2003-02-19 | 2005-10-28 | 한국유나이티드제약 주식회사 | Soft capsule containing cyclosporin and it's manufacturing process |
GT200500310A (en) * | 2004-11-19 | 2006-06-19 | ORGANIC COMPOUNDS | |
GB0504950D0 (en) | 2005-03-10 | 2005-04-20 | Novartis Ag | Organic compositions |
JP4889262B2 (en) * | 2005-08-19 | 2012-03-07 | 理研ビタミン株式会社 | Fat-soluble drug composition |
MD3347G2 (en) * | 2006-12-26 | 2008-01-31 | Институт Сельскохозяйственной Техники "Mecagro" | Process for obtaining methyl esters from rapeseed oil |
ITPD20070049A1 (en) * | 2007-02-14 | 2008-08-15 | Sila S R L | CONJUGATED LINOLEIC ACID PRODUCT AND PROCESS FOR ITS MANUFACTURE |
JP2010523554A (en) | 2007-04-04 | 2010-07-15 | シグモイド・ファーマ・リミテッド | Pharmaceutical composition of tacrolimus |
CN101199836B (en) * | 2007-11-07 | 2011-03-30 | 安徽省药物研究所 | Stage releasing CsA solid tiny milk agent and tiny milk curing method thereof |
CA2762179A1 (en) | 2009-05-18 | 2010-11-25 | Sigmoid Pharma Limited | Composition comprising oil drops |
IN2012DN00781A (en) | 2009-08-12 | 2015-06-26 | Sigmoid Pharma Ltd | |
GB201020032D0 (en) | 2010-11-25 | 2011-01-12 | Sigmoid Pharma Ltd | Composition |
JO3337B1 (en) | 2010-12-13 | 2019-03-13 | Debiopharm Sa | Pharmaceutical Compositions Comprising Alisporivir |
FR2971941B1 (en) | 2011-02-24 | 2013-08-02 | Physica Pharma | SKIN ADMINISTRATIVE PHARMACEUTICAL COMPOSITIONS FOR LOCAL TREATMENT OF CANINE ATOPIC DERMATITIS |
GB201304662D0 (en) | 2013-03-14 | 2013-05-01 | Sigmoid Pharma Ltd | Compositions |
ES2858517T3 (en) | 2014-11-07 | 2021-09-30 | Sublimity Therapeutics Ltd | Compositions comprising cyclosporin |
WO2020050182A1 (en) * | 2018-09-06 | 2020-03-12 | 株式会社カマタ | Liquid composition for encapsulation and encapsulated formulation |
PT3886813T (en) * | 2018-11-26 | 2023-04-26 | Hepion Pharmaceuticals Inc | Pharmaceutical formulations of cyclosporine analogs |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1274354A (en) * | 1956-03-10 | 1961-10-27 | Surfactants obtained from triglycerides and polyethylene glycol | |
FI65914C (en) * | 1978-03-07 | 1984-08-10 | Sandoz Ag | FRAMEWORK FOR PHARMACEUTICAL COMPOSITION OF CYCLOSPORINE A |
CH641356A5 (en) * | 1979-02-27 | 1984-02-29 | Sandoz Ag | Pharmaceutical compositions containing cyclosporin |
PH19156A (en) * | 1982-02-01 | 1986-01-15 | Sandoz Ltd | Dihydrocyclosporin d in the treatment of multiple sclerosis |
GB8903804D0 (en) * | 1989-02-20 | 1989-04-05 | Sandoz Ltd | Improvements in or relating to organic compounds |
JPS62201591A (en) * | 1986-02-28 | 1987-09-05 | Shoichi Shimizu | Glycerolysis of oil and fat |
JP2632010B2 (en) * | 1988-01-29 | 1997-07-16 | 三共株式会社 | Cyclosporine preparation |
CH679119A5 (en) * | 1988-05-13 | 1991-12-31 | Sandoz Ag | |
HU201567B (en) * | 1988-07-21 | 1990-11-28 | Gyogyszerkutato Intezet | Process for production of intravenous medical compositions containing cyclosphorin |
KR0148748B1 (en) * | 1988-09-16 | 1998-08-17 | 장 크라메르, 한스 루돌프 하우스 | A multiphase cyclosporin composition |
GB8823621D0 (en) * | 1988-10-07 | 1988-11-16 | Madhok R | Compositions containing cyclosporins |
JPH0738771B2 (en) * | 1989-01-17 | 1995-05-01 | 花王株式会社 | Liquid edible oil composition |
BE1003009A5 (en) * | 1989-02-09 | 1991-10-22 | Sandoz Sa | NOVEL PHARMACEUTICAL COMPOSITIONS BASED ON CYCLOSPORINS. |
AU6785490A (en) * | 1989-12-18 | 1991-06-20 | Kraft General Foods, Inc. | Low-saturate edible oils and transesterification methods for production thereof |
GB9113872D0 (en) * | 1991-06-27 | 1991-08-14 | Sandoz Ag | Improvements in or relating to organic compounds |
-
1991
- 1991-06-27 GB GB919113872A patent/GB9113872D0/en active Pending
-
1992
- 1992-06-12 HU HU9201975A patent/HU216792B/en unknown
- 1992-06-15 DE DE4219526A patent/DE4219526C2/en not_active Expired - Lifetime
- 1992-06-15 DE DE4244986A patent/DE4244986B4/en not_active Expired - Lifetime
- 1992-06-15 DE DE4244930A patent/DE4244930C2/en not_active Expired - Lifetime
- 1992-06-23 IT ITRM920476A patent/IT1254401B/en active
- 1992-06-23 PT PT99106122T patent/PT953630E/en unknown
- 1992-06-23 ES ES99106122T patent/ES2227921T3/en not_active Expired - Lifetime
- 1992-06-23 EP EP92810479A patent/EP0539319B1/en not_active Expired - Lifetime
- 1992-06-23 ES ES92810479T patent/ES2142818T3/en not_active Expired - Lifetime
- 1992-06-23 DK DK99106122T patent/DK0953630T3/en active
- 1992-06-23 CH CH1971/92A patent/CH684163A5/en not_active IP Right Cessation
- 1992-06-23 CH CH296/94A patent/CH685764A5/en not_active IP Right Cessation
- 1992-06-23 EP EP99106122A patent/EP0953630B1/en not_active Expired - Lifetime
- 1992-06-23 PT PT92810479T patent/PT539319E/en unknown
- 1992-06-23 DK DK92810479T patent/DK0539319T3/en active
- 1992-06-24 CY CY190692A patent/CY1906A/en unknown
- 1992-06-24 FR FR9207856A patent/FR2678169B1/en not_active Expired - Lifetime
- 1992-06-24 MX MX9203236A patent/MX9203236A/en unknown
- 1992-06-24 GB GB9213393A patent/GB2257359B/en not_active Expired - Lifetime
- 1992-06-25 SK SK1977-92A patent/SK278759B6/en not_active IP Right Cessation
- 1992-06-25 NZ NZ243309A patent/NZ243309A/en not_active IP Right Cessation
- 1992-06-25 AU AU18527/92A patent/AU659460B2/en not_active Expired
- 1992-06-25 PH PH44558A patent/PH30337A/en unknown
- 1992-06-25 MY MYPI92001199A patent/MY109512A/en unknown
- 1992-06-25 AT AT0129892A patent/AT403436B/en not_active IP Right Cessation
- 1992-06-25 ZA ZA924719A patent/ZA924719B/en unknown
- 1992-06-25 CZ CS921977A patent/CZ281790B6/en not_active IP Right Cessation
- 1992-06-25 IL IL11854692A patent/IL118546A/en not_active IP Right Cessation
- 1992-06-25 NO NO922506A patent/NO303964B1/en not_active IP Right Cessation
- 1992-06-25 LU LU88138A patent/LU88138A1/en unknown
- 1992-06-25 IL IL102310A patent/IL102310A/en not_active IP Right Cessation
- 1992-06-25 FI FI922958A patent/FI109454B/en not_active IP Right Cessation
- 1992-06-26 RO RO92-0868A patent/RO111021B1/en unknown
- 1992-06-26 CA CA002175842A patent/CA2175842C/en not_active Expired - Lifetime
- 1992-06-26 RU SU5052126/A patent/RU2143919C1/en active
- 1992-06-26 JP JP4168946A patent/JP2653958B2/en not_active Expired - Lifetime
- 1992-06-26 CA CA002072509A patent/CA2072509C/en not_active Expired - Lifetime
- 1992-06-26 KR KR1019920011198A patent/KR0131064B1/en not_active IP Right Cessation
- 1992-06-29 TW TW081105112A patent/TW267943B/zh not_active IP Right Cessation
- 1992-07-01 IE IE922082A patent/IE73662B1/en not_active IP Right Cessation
- 1992-10-31 SA SA92130213A patent/SA92130213B1/en unknown
-
1993
- 1993-01-01 CN CN93100563A patent/CN1077798C/en not_active Expired - Lifetime
- 1993-02-01 FR FR9301141A patent/FR2685706A1/en active Granted
- 1993-06-18 UA UA93003147A patent/UA35559C2/en unknown
-
1994
- 1994-11-09 EE EE9400190A patent/EE03108B1/en unknown
- 1994-11-30 UY UY23864A patent/UY23864A1/en not_active IP Right Cessation
-
1995
- 1995-06-14 RO RO95-01142A patent/RO111110B1/en unknown
-
1996
- 1996-04-03 FI FI961513A patent/FI116199B/en not_active IP Right Cessation
- 1996-04-03 HK HK57196A patent/HK57196A/en not_active IP Right Cessation
- 1996-06-03 IL IL11854696A patent/IL118546A0/en unknown
- 1996-08-22 HK HK157696A patent/HK157696A/en not_active IP Right Cessation
- 1996-09-12 JP JP24170596A patent/JP3420897B2/en not_active Expired - Lifetime
- 1996-10-15 NO NO19964382A patent/NO325267B1/en not_active IP Right Cessation
-
1997
- 1997-06-20 KR KR1019970026005A patent/KR100231385B1/en not_active IP Right Cessation
-
1998
- 1998-09-22 KR KR1019980039160A patent/KR100231384B1/en not_active IP Right Cessation
-
2000
- 2000-01-14 GR GR20000400064T patent/GR3032366T3/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0539319B1 (en) | Pharmaceutical cyclosporin composition | |
US6844459B2 (en) | Pharmaceutical Composition | |
EP0589843B1 (en) | Pharmaceutical compositions containing cyclosporins | |
US6767555B2 (en) | Pharmaceutical compositions | |
GB2284615A (en) | Transesterified corn oil products | |
GB2315216A (en) | Microemulsion preconcentrates comprising FK 506 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK9A | Patent expired |